Cure8 research brief
If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and monitoring.
Patients with Crohn’s disease considering or starting biologic therapy, clinicians who manage IBD and monitor biomarkers, and researchers studying predictive biomarkers for treatment response.
The paper is a retrospective clinical study analyzing LRG as a candidate blood biomarker for predicting treatment response in Crohn’s disease. LRG correlated with CDAI and the reported cut-off had good discriminatory performance in this sample.
The study also compared one-year drug persistence for anti-TNF therapies versus ustekinumab and observed differences favoring anti-TNFs; for ustekinumab, lower baseline LRG trended toward continued treatment.
How to read this: This is an observational, retrospective analysis reported in a journal abstract; it can suggest associations but does not prove cause-effect or establish clinical guidelines. The LRG threshold and persistence findings will need confirmation in larger, prospective cohorts before being used to guide individual treatment decisions.
This is a retrospective study reported in an abstract/full-text from a specialty journal; findings are preliminary and need prospective validation. The reported LRG cut-off and drug persistence differences are from the study cohort and should not be directly applied as clinical rules.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
